Drugs Made In America Acquisition Corp.

Drugs Made In America Acquisition Corp. (Nasdaq: DMAA) is a blank-check company focused on the pharmaceutical and domestic drug manufacturing sector. The SPAC filed a Form 10-Q with the SEC on May 20, 2025, under accession number 0001213900-25-046061, reflecting its continued operations as a registered shell company actively pursuing a business combination. DMAA's mandate centers on identifying acquisition targets within U.S.-based pharmaceutical manufacturing and related life sciences industries, a sector that has attracted heightened investor and policy attention in recent years. For comprehensive data on DMAA's filings, deal status, and comparable SPAC activity, sign up for full access at SpacDesk.